Notably, a meta-analysis focusing on the severe toxic effects associated with ICIs found a significantly increased incidence of myositis, when anti-CTLA4 and anti-PD1 or PD-L1 were administered in combination [4]. The gene discussed is PDCD1; the disease is myositis disease.